Evelo Forges Ahead In Psoriasis As Atopic Dermatitis Pathway Narrows
Company Reveals Layoffs To Stay On Course
The company said the first three cohorts of its Phase II atopic dermatitis study failed, while another trial with a faster-release formulation of EDP1815 continues, along with a Phase III study in psoriasis.
